Literature DB >> 16254112

Prognostic value of activated Akt expression in oral squamous cell carcinoma.

J Lim1, J-H Kim, J-Y Paeng, M-J Kim, S-D Hong, J-I Lee, S-P Hong.   

Abstract

BACKGROUND: Akt is a serine/threonine kinase that plays an important role in tumorigenesis and influences prognosis in several cancers. However, its importance in oral squamous cell carcinomas (OSCC) has not been elucidated. AIM: To investigate the association between the expression of activated Akt, clinicopathological factors, and E-cadherin, PCNA (proliferating cell nuclear antigen), and VEGF (vascular endothelial growth factor) expression to verify the validity of Akt as a prognostic factor in OSCC.
METHODS: Phosphorylated Akt (p-Akt), E-cadherin, PCNA, and VEGF expression were assessed immunohistochemically in 84 OSCCs. The results were analysed in relation to clinicopathological factors.
RESULTS: p-Akt was expressed in 29 cases. It was significantly correlated with lymph node metastasis, TNM stage, and E-cadherin expression. Univariate analysis showed that p-Akt expression, E-cadherin expression, PCNA expression, differentiation, tumour size, lymph node metastasis, TNM stage, and recurrence correlated with prognosis. Multivariate analysis showed that p-Akt expression is an independent prognostic factor in patients with OSCC.
CONCLUSIONS: This study revealed that Akt activation is a significant prognostic indicator for OSCC and is correlated with E-cadherin expression. The inhibition of Akt is a possible molecular approach to the treatment of OSCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254112      PMCID: PMC1770780          DOI: 10.1136/jcp.2004.024786

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  31 in total

Review 1.  AKT plays a central role in tumorigenesis.

Authors:  J R Testa; A Bellacosa
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

2.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

Authors:  J Brognard; A S Clark; Y Ni; P A Dennis
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

3.  High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity.

Authors:  H Nakayama; T Ikebe; M Beppu; K Shirasuna
Journal:  Cancer       Date:  2001-12-15       Impact factor: 6.860

4.  CD44 as prognostic factor in oral and oropharyngeal squamous cell carcinoma.

Authors:  Francesco Carinci; Giordano Stabellini; Mario Calvitti; Stefano Pelucchi; Lorenza Targa; Antonio Farina; Furio Pezzetti; Antonio Pastore
Journal:  J Craniofac Surg       Date:  2002-01       Impact factor: 1.046

5.  Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells.

Authors:  A A Thant; A Nawa; F Kikkawa; Y Ichigotani; Y Zhang; T T Sein; A R Amin; M Hamaguchi
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

6.  Prevalence of p53, bcl-2, and Ki-67 immunoreactivity and of apoptosis in normal oral epithelium and in premalignant and malignant lesions of the oral cavity.

Authors:  Adriano Piattelli; Corrado Rubini; Massimiliano Fioroni; Giovanna Iezzi; Alfredo Santinelli
Journal:  J Oral Maxillofac Surg       Date:  2002-05       Impact factor: 1.895

7.  Overexpression and overactivation of Akt in thyroid carcinoma.

Authors:  M D Ringel; N Hayre; J Saito; B Saunier; F Schuppert; H Burch; V Bernet; K D Burman; L D Kohn; M Saji
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

8.  Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

Authors:  Shazli N Malik; Michael Brattain; Paramita M Ghosh; Dean A Troyer; Thomas Prihoda; Roble Bedolla; Jeffrey I Kreisberg
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

9.  Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.

Authors:  Anjali K Gupta; W Gillies McKenna; Charles N Weber; Michael D Feldman; Jeffrey D Goldsmith; Rosemarie Mick; Mitchell Machtay; David I Rosenthal; Vincent J Bakanauskas; George J Cerniglia; Eric J Bernhard; Randal S Weber; Ruth J Muschel
Journal:  Clin Cancer Res       Date:  2002-03       Impact factor: 12.531

10.  Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells.

Authors:  B K Park; X Zeng; R I Glazer
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

View more
  31 in total

1.  Expression of E-cadherin, Twist, and p53 and their prognostic value in patients with oral squamous cell carcinoma.

Authors:  Chi-Chen Fan; Tao-Yeuan Wang; Yen-An Cheng; Shih Sheng Jiang; Chien-Wen Cheng; Alan Yueh-Luen Lee; Ting-Yu Kao
Journal:  J Cancer Res Clin Oncol       Date:  2013-08-30       Impact factor: 4.553

2.  Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer.

Authors:  Liwei Bao; Michael A Gorin; Manchao Zhang; Alejandra C Ventura; William C Pomerantz; Sofia D Merajver; Theodoros N Teknos; Anna K Mapp; Quintin Pan
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

Review 3.  Antineoplastic effects of mammalian target of rapamycine inhibitors.

Authors:  Maurizio Salvadori
Journal:  World J Transplant       Date:  2012-10-24

4.  Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma.

Authors:  Jacob I Tower; Mark W Lingen; Tanguy Y Seiwert; Alexander Langerman
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

5.  PTEN-mediated AKT activation contributes to the reduced apoptosis among Indian oral squamous cell carcinoma patients.

Authors:  Nisreen Sherif Alyasiri; Syed Jafar Mehdi; M Shabbir Alam; Asgar Ali; Ashish K Mandal; Sunita Gupta; Ishwar Singh; M Moshahid Alam Rizvi
Journal:  J Cancer Res Clin Oncol       Date:  2011-10-28       Impact factor: 4.553

6.  Pathologic significance of AKT, mTOR, and GSK3β proteins in oral squamous cell carcinoma-affected patients.

Authors:  Flávia Sayuri Matsuo; Marília Ferreira Andrade; Adriano Mota Loyola; Sindeval José da Silva; Marcelo José Barbosa Silva; Sérgio Vitorino Cardoso; Paulo Rogério de Faria
Journal:  Virchows Arch       Date:  2018-04-30       Impact factor: 4.064

Review 7.  Glycogen synthase kinase 3 beta: can it be a target for oral cancer.

Authors:  Rajakishore Mishra
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

8.  Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer.

Authors:  Carmen M Klass; Mi Sun Choe; Selwyn J Hurwitz; Mourad Tighiouart; Xin Zhang; Zhuo Georgia Chen; Dong M Shin
Journal:  Head Neck       Date:  2009-10       Impact factor: 3.147

9.  Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells.

Authors:  Kyoung-Ok Hong; Ji-Hong Kim; Ji-Soo Hong; Hye-Jung Yoon; Jae-Il Lee; Sam-Pyo Hong; Seong-Doo Hong
Journal:  J Exp Clin Cancer Res       Date:  2009-02-26

10.  Inhibition of Cell Proliferation and MAP Kinase and Akt Pathways in Oral Squamous cell Carcinoma by Genistein and Biochanin A.

Authors:  Tara L Johnson; Maria B Lai; James C K Lai; Alok Bhushan
Journal:  Evid Based Complement Alternat Med       Date:  2008-02-29       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.